ClinicalTrials HQ

Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

Active, not recruiting · NCT02393794 · Registry updated 2025-10-06
Ask about research services

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinomaActive, not recruitingPhase 1 / Phase 22025-10-06NCT02393794

3 results · Page 1 of 1

Organizations

Swipe the table sideways for more columns.

OrganizationsLinked trials
Bristol-Myers Squibb422
Celgene Corporation20
Priyanka Sharma2

7 results · Page 1 of 1

Research sites

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
University of Kansas Cancer Center - Clinical Research CenterFairwayUnited States1
University of Kansas Cancer Center - Lee's SummitLee's SummitUnited States158
University of Kansas Cancer Center - NorthKansas CityUnited States162
University of Kansas Cancer Center - Overland ParkOverland ParkUnited States4
University of Kansas Cancer Center - SouthKansas CityUnited States2
University of Kansas Cancer Center - WestKansas CityUnited States2
University of Kansas Cancer Center - WestwoodWestwoodUnited States6